HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Akihito Inagaki Selected Research

Fluorouracil (Carac)

11/2022Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer.
1/2018Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
7/2017Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
7/2017Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
10/2014Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
1/2012Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Akihito Inagaki Research Topics

Disease

12Neoplasms (Cancer)
11/2022 - 08/2007
5Glioma (Gliomas)
11/2022 - 10/2014
5Brain Neoplasms (Brain Tumor)
01/2015 - 09/2007
3Glioblastoma (Glioblastoma Multiforme)
01/2016 - 08/2007
1Lung Neoplasms (Lung Cancer)
11/2022
1Adenocarcinoma
01/2018
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2018
1Breast Neoplasms (Breast Cancer)
08/2013
1Infections
01/2012
1Carcinogenesis
08/2007
1Hemorrhage
08/2007

Drug/Important Bio-Agent (IBA)

7Flucytosine (Ancobon)FDA Link
11/2022 - 01/2012
7ProdrugsIBA
11/2022 - 01/2012
6vocimagene amiretrorepvecIBA
11/2022 - 01/2012
6Fluorouracil (Carac)FDA LinkGeneric
11/2022 - 01/2012
6Cytosine DeaminaseIBA
11/2022 - 01/2012
1Neoplasm Antigens (Tumor Antigens)IBA
07/2017
1CytokinesIBA
01/2016
1Interleukin-6 (Interleukin 6)IBA
01/2016
1ChemokinesIBA
01/2016
1Interleukin-8 (Interleukin 8)IBA
01/2016
1InterferonsIBA
01/2016
1Interleukin-2 (IL2)IBA
01/2015
1Delayed-Action PreparationsIBA
10/2014
1Proteins (Proteins, Gene)FDA Link
05/2014
1Indicators and Reagents (Reagents)IBA
05/2014
1IntegrinsIBA
05/2014
1src-Family KinasesIBA
05/2014
1Focal Adhesion Protein-Tyrosine KinasesIBA
05/2014
1salicylhydroxamic acid (SHAM)IBA
08/2013
1Tyrosine Kinase InhibitorsIBA
04/2008
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2008
1NestinIBA
04/2008
1Epidermal Growth Factor (EGF)IBA
04/2008
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2007

Therapy/Procedure

2Radiotherapy
10/2014 - 05/2014
2Therapeutics
05/2014 - 08/2013
2Transplantation
04/2008 - 09/2007